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Abstract
Aims: The effect of undertreatment with adjuvant hormonal therapy, chemotherapy or radiation was studied in
elderly women with breast cancer.
Methods: A prospectively maintained database was used to identify women undergoing potentially curative
surgery between 1997 and 2011. The presentation, pathologic findings, treatment and outcomes of 449 women
over 65 were compared to the findings in 1049 younger patients. Moreover, conventionally treated and
undertreated elderly patients were identified and their characteristics and outcomes were compared.
Results: Both young and old patients presented most frequently with mammographic findings, but older patients
presented more frequently with mammographic masses while younger patients presented more frequently with
mammographic calcifications. Cancers of older patients were signicantly more favorable than cancers in younger
patients with more infiltrating lobular, fewer ductal carcinoma in situ and more frequently estrogen receptor
positive and fewer were poorly differentiated. Elderly patients had less axillary surgery, less adjuvant radiation
therapy and more hormonal therapy. Fourty-six percent of the 449 elderly patients were undertreated by
conventional criteria. Undertreated patients were more frequently in situ, better differentiated, smaller, and more
often estrogen receptor positive. Forty-four percent of the undertreated patients died during follow-up without
disease recurrence.
Conclusions: Despite undertreatment, local and distant disease-free survival was comparable to patients who were
not undertreated.
Introduction
The population of elderly individuals in developed coun-
tries is increasing. Between 2000 and 2010 the popula-
tion of women aged 65 and over increased by 11.3%
with those 70 and over increasing by 6.4% [1]. Accord-
ing to the Surveillance Epidemiology and End Results
(SEERs) database, from 2000 to 2009 the median age for
breast cancer diagnoses in the USA was 61 years of age.
Approximately 41% were diagnosed above the age of 65,
of which 21% were above the age of 75 [2]. As the
developed countries population of women over 65
increases, breast cancer in older individuals has and will
continue to become more prevalent.
The management of breast cancer in the elderly has
been a topic of debate. There is a lack of evidence on
the optimal management of this group of patients sec-
ondary to low enrollment in randomized clinical trials
[3,4]. As a result, treatment decisions have been largely
based on studies in younger patients which may not be
applicable to elderly patients with breast cancer.
Breast cancers in elderly women compared to younger
women are histologically less aggressive and have a good
response to hormonal therapy. This favorable biologic
profile impacts the decision as to whether an elderly
patient should be subjected to adjuvant therapy.
The consequences of these considerations are that
elderly patients are often undertreated when compared
to younger patients [5-7], but the question that needs to
be answered is: are there any clinical implications to the
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undertreatment of breast cancer in elderly women
[6,8,9].
Diab and colleagues demonstrated that the impact of
breast cancer on the expected survival of these elderly
patients decreases with age [9] and the risk of dying
from comorbid conditions often exceeds the risk of can-
cer recurrence and breast cancer mortality [10].
Although recommendations based on expert opinion are
emerging, there is a paucity of level 1 evidence [11,12].
Determining the optimal treatment for an elderly
patient depends largely on clinical judgement, weighing
the patients’ comorbid conditions with the biology of
the tumor [13].
Methods
We reviewed our breast cancer database with the fol-
low-up of patients who have been cared at General and
Geriatric Surgery Department of University of Naples
“Federico II” from 1997 to 2011. Women 65 years of
age and older at the time of diagnosis (449) were identi-
fied and compared to women younger than 65 years of
age at the time of diagnosis (1049).
Data were collected on age, clinical presentation, mam-
mographic findings, diagnostic method, histopathologic
findings, tumor differentiation, tumor size, estrogen
receptor status, axillary node status, resection margins,
number of pathologically examined nodes, surgical treat-
ment, re-excision, adjuvant hormone treatment, che-
motherapy and radiation therapy. Follow-up information
was acquired from hospital and office records, patients,
and their families. The last date of follow-up and the date
of local or distant recurrence were recorded.
The local and distant disease free survival rates were then
calculated from the date of definitive surgery. For estimates
of local and distant disease recurrence rates, patients in
whom a recurrence did not develop were censored at the
last follow-up or death, whichever occurred first.
Patients over 65 years of age who were undertreated
by conventional criteria were compared to their appro-
priately treated counterparts. Our criteria for under-
treatment included: (1) omission of axillary surgery in
patients with invasive cancers; (2) lack of postoperative
radiation therapy in patients treated with breast conser-
ving surgery; (3) lack of hormonal treatment in estrogen
receptor positive patients with invasive cancers; (4) lack
of chemotherapy in node-positive patients; (5) lack of
chemotherapy in estrogen receptor negative patients
with tumors larger than 2 cm.
The patients were divided into two groups by age
(younger than 65 vs. 65 and over) and compared.
The signicance of differences in discrete variables was
evaluated using chi-square test, and the signicance of
differences in continuous variables was evaluated using
Student’s t - test.
Results
The 1498 patients ranged in age from 20 to 92 years
and 449 (30%) were of age 65 and above, considered
elderly (Table 1).
The 1049 younger patients ranged in age from 20 to
65, with a median age of 47 and the patients over
65 years ranged in age from 65 to 92 years with a med-
ian age of 76.
Most patients presented with a palpable mass (31%).
Older patients presented more frequently with mammo-
graphic masses while younger patients presented more
frequently with mammographic calcifications. Both the
elderly and the younger patients were most commonly
diagnosed by fine-needle aspiration followed by core
needle biopsy and excisional biopsy.
Numerous signicant differences were observed
between the elderly and younger patients in terms of
their pathology (Table 2).
Older patients had signicantly more infiltrating lobular
cancers and fewer cases of ductal carcinoma in situ than
younger patients and signicantly fewer poorly differen-
tiated cancers. The T stage distribution among the
elderly and younger patients was comparable. Estrogen
receptor positivity was more frequent among the elderly.
Axillary node sampling, sentinel node excision or axil-
lary dissection was more frequent in younger patients.
Adjuvant therapy with both radiation and chemother-
apy was significantly less frequent in the elderly.
97% of the 776 young patients treated with breast
conservation received radiation therapy compared to
53% of the 125 elderly patients treated with breast con-
servation (p < 0.001).
Among patients with invasive cancers, 18% of the
young patients received neoadjuvant chemotherapy and
35% adjuvant chemotherapy compared to 3% and 8% of
the comparable elderly patients (p < 0.001).
Table 1 Demographic variables in patients < 65 years
and > 65 years.
Demographic variable < 65 years > 65 years p
N 1049 449
Mean age (years) 52 76
Presentation
Palpable mass 314 (31%) 130 (29%) NS
Mx calcification 304 (29%) 63 (14%) <0.01
Mx mass 199 (19%) 130 (29%) <0.01
Mx abnormality 10 (1%) 4 (1%) NS
Other 222 (20%) 122 (27%) <0.01
Diagnostic method
Excisional biopsy 241 (23%) 108 (24%) NS
Fine-needle aspiration 524 (50%) 229 (51%) NS
Core Needle aspiration 283 (27%) 112 (25%) NS
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The main form of systemic therapy for the elderly
patient was hormonal: either Tamoxifen or Aromatase
inhibitor.
Despite these differences, the elderly and younger
patients had similar 5-year local and distant recurrence-
free survival (Table 3).
Undertreated elderly patients were identified as
described above.
Undertreatment consisted of omission of radiation
therapy in 59 of the 125 patients treated with breast
conservation, omission of axillary node surgery in 301 of
the 377 elderly patients with invasive cancers, omission
of chemotherapy in 66 of 102 elderly patients with
involved nodes, and omission of hormonal therapy in 85
of 386 elderly patients with estrogen receptor positive
cancers.
By these criteria many patients were undertreated with
more than one modality. As a consequence, 206 (46%)
of the elderly patients were undertreated with at least
one modality.
The cancers of the undertreated elderly were more
frequently in situ, better differentiated and more often
estrogen receptor positive (Table 4).
Reflecting the criteria used to identify undertreated
patients, two-thirds did not receive radiation, almost
half did not receive hormonal therapy and a few
received chemotherapy.
Despite these differences in treatment, elderly under-
treated patients generally fared as well as the appropri-
ately treated elderly (Table 5). Equal numbers of
patients in both groups developed local recurrences
resulting in five-year cumulative local disease-free rates
of 94% for the appropriately treated and 93% for the
undertreated.
9% of the 218 appropriately treated elderly patients
with invasive cancers developed distant disease com-
pared to 4% of undertreated patients causing the cumu-
lative five-year distant disease free rate to be 89% in
appropriately treated patients compared to 93% in the
undertreated one.
Undertreatment was not significantly related to local
or distant recurrence (RR 1.01 [C.I. 0.45-2.27] and 0.46
[C.I. 0.18-1.12] respectively).
Discussion
This study found that elderly patients with breast cancer
present with palpable masses and mammographic find-
ings similar to younger patients, although mammo-
graphic masses were more frequent in the elderly and
mammographic calcifications were more frequent
among the young patients.
Cancers of the elderly tended to be less often in situ
than in younger patients but invasive cancers were gen-
erally better differentiated, more frequently estrogen
receptor positive, and with less nodal involvement.
Older patients were treated less aggressively than
younger patients. They received less radiation after
breast conservation and very seldom they received che-
motherapy even for node-positive cases. Elderly patients
received hormonal therapy as frequently as younger
patients. Despite often being undertreated, elderly
patients experienced outcomes comparable to younger
patients presumably because their cancers were better
differentiated and with fewer involved nodes.
More than one-half of our elderly patients were under-
treated according to current breast cancer treatment
guidelines: omission of axillary surgery in patients with
invasive cancers, omission of radiation in patients treated
with breast conservation, omission of chemotherapy in
patients with involved nodes or omission of hormonal
therapy in patients with estrogen receptor positive can-
cers. Despite the large number of undertreated patients,
Table 2 Pathologic findings in patients < 65 years and
> 65 years.
Pathologic finding < 65 years > 65 years P value
Histopathology
Infiltrating ductal 739 (70,5%) 323 (72%) NS
Infiltrating lobular 79 (7,5%) 54 (12%) <0,01
Ductal Carcinoma In Situ DCIS 231 (22%) 72 (16%) <0,01
Grading
G1 262 (25%) 112 (25%) NS
G2 451(43%) 238 (53%) <0,01
G3 336 (32%) 99 (22%) <0,01
Tumor size
Median 1.2 1.2 NS
0-2 786 (75%) 327 (73%) NS
2-5 199 (19%) 103 (23%) NS
>5 64 (6%) 19 (4%) NS
Node positive 245/818 (30%) 102/377 (27%) NS
Involved nodes
Mean 3.9 3.7 NS
0 573 (70%) 275 (73%) NS
1-3 155 (19%) 64 (17%) NS
>4 90 (11%) 38 (10%) NS
Estrogen receptor positive 797 (76%) 386 (86%) <0,01
Axillary node surgery 793 (97%) 301 (80%) <0,01
Surgery
Breast Conservation 776 (74%) 125 (28%) <0,001
Mastectomy 273 (26%) 324 (72%) <0,001
Neoadjuvant chemotherapy 189 (18%) 13 (3%) <0,001
Postoperative chemotherapy 367 (35%) 36 (8%) <0,001
Tamoxifen/Aromatase inhibitor 598/797 (75%) 301/386 (78%) NS
Radiation therapy after BCS 753/776 (97%) 66/125 (53%) <0,001
Rocco et al. BMC Surgery 2013, 13(Suppl 2):S26
http://www.biomedcentral.com/1471-2482/13/S2/S26
Page 3 of 6
there were no signicant differences in local or distant dis-
ease free survival among undertreated and appropriately
treated patients.
Previous studies of elderly patients with breast cancer
have not universally observed that cancers in the elderly
are biologically more favorable and less advanced than
those seen in younger patients. This is in part due to
differences in the populations studied. Generally when
one compares the cancers of patients over 65 to patients
between 50 and 65, differences are not striking [14,15].
However, if one includes all patients younger than 65,
the more favorable biology becomes more apparent [16].
In addition, many studies included elderly patients who
were not treated with surgery for a variety of reasons
including comorbidity, advanced disease, and patient
refusal [17-20]. All of the patients in the current study
were potentially curable at presentation, all had surgery
and no stage IV patients are included. A universal find-
ing in all the studies is the increasing frequency of
estrogen receptor positivity with increasing age. This
usually results in the increased use of hormonal thera-
pies in the elderly.
Undertreatment of the elderly is also a universal finding.
In fact several authors have found that undertreatment,
Table 3 Local and distant disease-free survival.
N Recurrence Cumulative 5-year recurrence-free survival (%) RR (95% CI) P value
Local recurrence
< 65 years 1049 58 94
>= 65 years 449 27 94 1.09 (0.68-1.73) NS
Distant recurrence
< 65 years 1049 84 92
>= 65 years 449 28 94 0.78 (0.50-1.20) NS
Table 4 Pathologic findings in undertreated and properly treated aged > 65 years.
Pathologic finding Full treatment Undertreated P value
Histopathology
Infiltrating ductal 199 (82%) 138 (67%) <0,01
Infiltrating lobular 19 (8%) 27 (13%) NS
DCIS 25 (10%) 41 (20%) <0,01
Grading
G1 34 (14%) 37 (18%) NS
G2 134 (55%) 140 (68%) <0,01
G3 75 (31%) 29 (14%) <0,01
Tumor size
Median 1.4 1.0
0-2 168 (69%) 159 (77%) NS
2-5 63 (26%) 39 (19%) NS
>5 12 (5%) 8 (4%) NS
Involved nodes
Mean 1.1 0.5
0 182 (75%) 167 (81%) NS
1-3 29 (12%) 29 (14%) NS
>4 31 (13%) 12 (6%) <0,05
Estrogen receptor positive 194 (80%) 185 (90%) <0,01
Surgery
Breast conservation 59 (24%) 66 (32%) NS
Mastectomy 184 (76%) 140 (68%) NS
Postoperative chemotherapy 66 (27%) 8 (4%) <0,01
Tamoxifen/Aromatase inhibitor 197 (81%) 107 (52%) <0,01
Radiation therapy 204 (84%) 62 (30%) <0,01
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that is lack of adherence to guidelines, is frequent at all
ages [14]. The controversy that exists is whether under-
treatment of patients, particularly the elderly, results in
adverse outcomes. There is no question that radiation
therapy reduces local recurrence rates after breast conser-
vation for invasive and in situ disease regardless of the
patient’s age. However, a reduction of 3% in local recur-
rence does not signicantly benefit an 80-year-old woman
with a life expectancy of ten years who has only a 50%
chance of experiencing the benefit of radiation therapy
[21].
Previous studies reported that elderly patients with
invasive cancers experience higher mortality when axil-
lary dissection is omitted [22]. Among these studies, a
few measured breast cancer specific survival. It is likely
that patients not undergoing axillary dissection have
higher comorbidities causing the higher mortality, not
that the omission of axillary surgery caused the higher
mortality. The recently completed trial randomizing
patients with involved sentinel nodes to completion axil-
lary dissection versus no additional surgery showed no
benefit for completion axillary dissection [23].
Finally, with respect to chemotherapy, a few elderly
patients are willing to participate in randomized trials
with chemotherapy arms and a few are willing to accept
chemotherapy even with relatively advanced disease
[3,4,24-26].
Only 63 of our elderly patients were estrogen receptor
negative and 16 of these had nodal involvement. All
received chemotherapy and an additional 11 patients with
node negative and estrogen receptor negative larger can-
cers received chemotherapy. Because of the small numbers
of patients and the association of chemotherapy with
advanced estrogen receptor negative disease, patients
receiving chemotherapy fared worse than patients not
receiving chemotherapy.
Potential limitations of this study derive from the study
design:. it is a retrospective database review (observational
study).
This includes a potential physician bias and bias as a
result of confounding by indication. It must be men-
tioned, however, that in today’s world of cancer
treatment, care is individualized and the patient ulti-
mately determines what treatment she is to receive.
Breast cancer in elderly patients has a favorable biolo-
gical profile and therefore treatment does not need to
fall under the confines of traditional guidelines. More-
over, coupled with comorbid conditions that are fre-
quently encountered as people age, optimal treatment
should be determined largely by clinical judgement on a
case by case basis. It is known that elderly patients are
undertreated but this study did not find that the omis-
sion of conventional surgery or adjuvant therapies
adversely affected outcome among patients over 65
years of age.
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Table 5 Local and distant disease-free survival in undertreated and properly treated patients aged > 65 years.
N Recurrence Cumulative 5-year recurrence-free survival (%) RR (95% CI) P value
Local recurrence
Undertreated 206 12 93
Properly treated 243 14 94 1.01 (0.45-2.27) NS
Distant recurrence*
Undetreated 165 7 93
Properly treated 218 20 89 0.46(0.18-1.12) NS
*Invasive cancers
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